Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
It is the generic version of molnupiravir
It has also been granted permission to conduct trials for booster dose
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Partnering to build biosynthesis processes and a pharmaceutical production platform
Subscribe To Our Newsletter & Stay Updated
